Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
269 studies found for:    "Alkylating Agents" | updated in the last 30 days
Show Display Options
Rank Status Study
1 Recruiting Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Conditions: Dyskeratosis Congenita;   Hoyeraal Hreidarsson Syndrome;   Revesz Syndrome;   Aplastic Anemia
Interventions: Biological: alemtuzumab;   Drug: Fludarabine;   Drug: Cyclosporins;   Drug: Mycophenolate mofetil
2 Recruiting Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Conditions: Histologically Confirmed Medulloblastoma;   Activation of the Sonic Hedgehog (SHH) Pathway
Interventions: Drug: vismodegib;   Drug: Temozolomide
3 Recruiting Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Condition: Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Drug: Standard of Care Chemotherapy
4 Recruiting Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
Condition: Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Interventions: Drug: AZD1775;   Drug: AZD1775 Matching Placebo;   Drug: pemetrexed;   Drug: carboplatin
5 Recruiting Cellular Immunotherapy After Cyclophosphamide in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Drug: cyclophosphamide;   Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells;   Other: laboratory biomarker analysis
6 Recruiting Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Intervention: Drug: trabectedin
7 Completed A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
Condition: Small Cell Lung Carcinoma
Intervention: Drug: Adriamycin, cyclophosphamide, vindesine, valproic acid
8 Recruiting Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
Conditions: Myeloid Leukemia;   Precursor Myeloid Neoplasms;   Lymphoid Neoplasms
Interventions: Drug: Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
9 Suspended Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Conditions: Acute Myeloid Leukemia;   Hematologic Malignancies;   Acute Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma,;   Multiple Myeloma;   Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Myelofibrosis;   Myeloproliferative Syndrome
Interventions: Radiation: total marrow irradiation;   Drug: fludarabine phosphate;   Drug: busulfan;   Procedure: myeloid progenitor cell transplantation;   Biological: anti-thymocyte globulin;   Drug: tacrolimus;   Drug: methotrexate;   Other: laboratory biomarker analysis
10 Recruiting Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Condition: Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ponatinib;   Drug: G-CSF  (Filgrastim);   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Solu-medrol ( Methyl Prednisolone);   Drug: Citrovorum (Leucovorin);   Drug: Prednisone;   Drug: Pegfilgrastim (Neulasta)
11 Recruiting Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Pancreatic Cancer;   Somatostatinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: capecitabine;   Drug: temozolomide;   Biological: bevacizumab
12 Recruiting Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Conditions: Adult Brain Glioblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Drug: Temozolomide;   Drug: Veliparib;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
13 Recruiting Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Cyclophosphamide;   Drug: Ixazomib (MLN9708);   Drug: Dexamethasone
14 Active, not recruiting Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Conditions: Breast Adenocarcinoma;   HER2 Positive Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Cyclophosphamide;   Drug: Paclitaxel;   Biological: Trastuzumab;   Drug: Tamoxifen Citrate;   Drug: Aromatase Inhibition Therapy;   Other: Laboratory Biomarker Analysis
15 Active, not recruiting Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients
Condition: Glioblastoma
Interventions: Drug: Temozolomide;   Radiation: Radiation Therapy
16 Recruiting Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
Condition: Melanoma
Interventions: Drug: cyclophosphamide;   Biological: Mature dendritic cell vaccine
17 Active, not recruiting Veliparib and Temozolomide in Treating Patients With Acute Leukemia
Conditions: Accelerated Phase of Disease;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Adult B Acute Lymphoblastic Leukemia;   Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Adult T Acute Lymphoblastic Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Blastic Phase;   Chronic Myelomonocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Disease;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
18 Recruiting Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: busulfan;   Drug: fludarabine phosphate;   Radiation: total-body irradiation (TBI);   Procedure: Stem cell transplant;   Drug: cyclophosphamide
19 Recruiting Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Glufosfamide;   Drug: Fluorouracil
20 Recruiting Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
Conditions: Stage II Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Drug: Lenalidomide;   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Prednisone;   Other: Laboratory Biomarker Analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years